
MK 571
CAS No. 115104-28-4
MK 571( L-660711 | L660711 | MK-571 )
Catalog No. M21561 CAS No. 115104-28-4
MK 571 is an orally active antagonist of CysLT1 receptor .
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 74 | Get Quote |
![]() ![]() |
10MG | 115 | Get Quote |
![]() ![]() |
25MG | 235 | Get Quote |
![]() ![]() |
50MG | 348 | Get Quote |
![]() ![]() |
100MG | 518 | Get Quote |
![]() ![]() |
500MG | 1134 | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameMK 571
-
NoteResearch use only, not for human use.
-
Brief DescriptionMK 571 is an orally active antagonist of CysLT1 receptor .
-
DescriptionMK 571 is an orally active antagonist of CysLT1 receptor.
-
In VitroCell Viability Assay Cell Line:RBL-2H3 cells, human LAD2 mast cells Concentration:15 μM Incubation Time:1 h Result:Inhibited S1P secretion by vector and SphK1 transfected RBL-2H3 cells, whereas it did not affect uptake and intracellular conversion of [3H]Sph to S1P. Inhibited Fluo-3 efflux, inhibited S1P export by LAD2 cells, and blocked Ag-stimulated release of S1P.
-
In VivoAnimal Model:Hyperreactive rats (male and female, 200-400 g, pretreated intravenously with 3μg/kg methysergide, 5 min before antigen chdlenge)Dosage:0.5, 0.15, and 0.05 mg/kgAdministration:Orally, once, 1 or 4 h before challengeResult:Produced dose-dependent inhibition of the duration of antigen-induced dyspnea, with ED50 values of 0.13 (95% confidence interval (CI), 0.03-0.62) and 0.11 (95% CI, 0.009-1.47) mg/kg, respectively. MK-571 was even more active when administered orally as a suspension in 1% Methocel (4 h pretreatment), with an ED50 of 0.068 (95% CI, 0.83-0.14) mg/kg.Animal Model:Csnscisus squirrel msnkeys Dosage:0.1, 0.5, and 1 mg/kg Administration:Orally, once, 2 h prior to challenge with Ascaris antigenResult:Produced significant inhibition of the bronchoconstriction at 0.5 mg/kg, produced significant inhibition of the increases in RL and decreases in Cdyn at 1 mg/kg.Animal Model:FVB (Friend virus B-type) mice (Mrp4–/– and WT, 6 weeks old, exposed to chronic hypoxia (10% O2) in a ventilated chamber for 28 days)Dosage:0, 5, and 25 mg/kg Administration:Orally, daily, for 2 more weeks, maintain in hypoxic conditionsResult:Showed reversal of hypoxic pulmonary hypertension (PH), and mice were protected from hypoxic PH. MK-571-treated mice displayed lower RVSP and Fulton index and a decrease in the medial thickening of small pulmonary arteries and arterioles.
-
SynonymsL-660711 | L660711 | MK-571
-
PathwayImmunology/Inflammation
-
TargetLTR
-
RecptorCysLTR1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number115104-28-4
-
Formula Weight515.09
-
Molecular FormulaC26H26ClN2NaO3S2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCN(C)C(=O)CCSC(SCCC(O)=O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Lynch K R O'Neill G P Liu Q et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor[J]. Nature 1999 399(6738):789-793.
molnova catalog


